Kahn Swick & Foti Investigates Verrica Pharmaceuticals Inc.
The law firm Kahn Swick & Foti, LLC (KSF), under the leadership of former Louisiana Attorney General Charles C. Foti, Jr., has launched an investigation into Verrica Pharmaceuticals Inc. (NASDAQ: VRCA). The inquiry is aimed at uncovering whether the company’s officers and directors have violated their fiduciary responsibilities towards shareholders, especially in light of the company's current legal challenges and issues with compliance.
Regulatory Concerns Facing the Company
Verrica Pharmaceuticals is grappling with a complicated regulatory landscape. In December 2020, the company submitted a New Drug Application (NDA) to the FDA for its primary product, VP-102 or YCANTH, which is designed to treat molluscum contagiosum, a viral skin disorder. The approval process has been anything but smooth. On September 20, 2021, Verrica announced it received a Complete Response Letter (CRL) from the FDA, pointing out deficiencies at the facility managed by its contract manufacturer—a significant hurdle for the company.
Resubmission of the New Drug Application
After addressing the issues highlighted in the FDA inspection, Verrica resubmitted its NDA in November 2021. This step was intended to rectify the deficiencies identified during the initial assessment. However, on May 24, 2022, the company was hit with yet another CRL, which noted ongoing concerns found during a general reinspection of the manufacturing site run by Sterling Pharmaceuticals Services. These challenges have raised concerns for both investors and regulators.
Legal Scrutiny through a Securities Class Action Lawsuit
The difficulties encountered by Verrica Pharmaceuticals have also resulted in legal challenges. A securities class action lawsuit has been filed against the company and several of its executives, accusing them of not disclosing critical information during a specific Class Period, which led to violations of federal securities laws. Recently, the court partially denied the company’s motion to dismiss, allowing this lawsuit to proceed and adding to the complexities surrounding the company.
What the Investigation Focuses On
As KSF continues its investigation, the primary focus is on whether the officers and directors fulfilled their fiduciary duties to the company's shareholders. This inquiry is vital as it could influence the potential financial recovery for those impacted by the recent turmoil in the company's operations.
How KSF Can Help Investors
Investors with information pertinent to KSF’s investigation, or those who have held shares of Verrica for an extended time, are encouraged to contact the firm. KSF offers a free initial consultation to discuss your legal rights in relation to this case. If you believe you may have been affected by the company's actions, don't hesitate to call their toll-free number at 1-833-938-0905.
Contacting KSF
For additional inquiries, individuals can also reach out directly to KSF Managing Partner Lewis Kahn via email. The firm is dedicated to supporting clients without any obligation, ensuring that all investor rights are protected.
About Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC has gained recognition as one of America’s leading boutique law firms specializing in securities litigation. Their expertise attracts a diverse clientele, including public institutional investors, retail investors, hedge funds, and money managers seeking compensation for losses caused by corporate fraud or misconduct. With offices across multiple states, such as New York and California, KSF is strategically positioned to support its clients effectively.
Frequently Asked Questions
What does Kahn Swick & Foti LLC aim to uncover?
They are investigating whether the officers and directors of Verrica Pharmaceuticals have breached their fiduciary duties to the shareholders.
What regulatory issues has Verrica Pharmaceuticals encountered?
Verrica received Complete Response Letters from the FDA regarding deficiencies found at their contract manufacturing facility.
What type of legal action is Verrica currently facing?
The company is involved in a securities class action lawsuit due to alleged failures in disclosing important information to its shareholders.
How can investors get in touch with KSF?
Investors can contact KSF at 1-833-938-0905 or reach out to Lewis Kahn via email for further details.
What assistance does KSF provide to investors?
KSF offers legal support to investors seeking recovery of losses related to corporate fraud and breaches of securities regulations.
